Escmid/asm Conference on Drug Development

The main goal of the conference is to explore ways to better preserve the efficacy of antibiotics in an era of escalating multi-drug resistance.

Conference Objectives:
Background: Antimicrobial drug resistance is an urgent problem. There are relatively few agents in developmental pipelines. Traditional pathways for drug development are expensive and slow. Both the EMA and FDA have recognized some of these obstacles for drug development. New regulation now enables accelerated drug development, with adaptive licensing until larger definitive phase III studies are completed. Such an approach enables access to drugs for patients with unmet medical needs.

Challenges: There is uncertainty regarding what constitutes reasonable pathways for accelerated drug development. There is a reliance on very robust preclinical studies, innovative clinical trial design, strong academicindustrial partnerships, and a requirement for early engagement with regulatory bodies.

Target Audience:
Specialists or physicians in training in infectious diseases, clinical microbiology and other disciplines dealing with the prudent use of antibiotics, clinical pharmacology, drug development, regulatory issues and health-care policies.

Organizing Committee:
David Hooper, Boston, MA, United States
William Hope, Liverpool, United Kingdom
Gunnar Kahlmeter, Växjö, Sweden
Ursula Theuretzbacher, Vienna, Austria

Programme Committee:
David Andes, Madison, WI, United States
Marco Cavaleri, London, United Kingdom
Ed Cox, Silver Spring, MD, United States
George Drusano, Lake Nona, FL, United States
William Hope, Liverpool, United Kingdom
Gunnar Kahlmeter, Växjö, Sweden
Jason Roberts, Brisbane, Australia
Keith Rodvold, Chicago, IL, United States
Ursula Theuretzbacher, Vienna, Austria

On Wednesday September 21, 2016 at 12:00 pm (ends Friday September 23, 2016 at 6:00 pm)

Category: Conferences - Science, Health & Medicine

Price:

ESCMID/ASM Members: EUR 80